Clinical Trial Update: Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the safety and tolerability of OCU-10-C-110 injections in participants with neovascular age-related macular degeneratio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• OCU-10-C-110

Snippet

Sponsor: Ocugenix Corporation | Conditions: Neovascular Age-related Macular Degeneration (nAMD) | Phase 1 | Status: RECRUITING